Compounds > doxazolidine
Page last updated: 2024-11-12

doxazolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

doxazolidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11599300
CHEMBL ID217089
SCHEMBL ID12567109
MeSH IDM0542203

Synonyms (4)

Synonym
doxazolidine
CHEMBL217089
SCHEMBL12567109
(7s,9s)-7-[[(3as,4s,6r,7as)-4-methyl-2,3a,4,6,7,7a-hexahydro-1h-pyrano[4,3-d][1,3]oxazol-6-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione

Research Excerpts

Overview

Doxazolidine (doxaz) is a new anthracycline anticancer agent. It induces cancer cell death in Dox-sensitive and resistant cells.

ExcerptReferenceRelevance
"Doxazolidine (Doxaz) is a functionally distinct formaldehyde conjugate of doxorubicin (Dox) that induces cancer cell death in Dox-sensitive and resistant cells. "( Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.
Barthel, BL; Chan, DC; Coldren, CD; Koch, GG; Koch, TH; Polinkovsky, M; Rudnicki, DL; Sun, H; Zhang, Z, 2009)		2.03
"Doxazolidine (doxaz) is a new anthracycline anticancer agent. "( Synthesis and biological characterization of protease-activated prodrugs of doxazolidine.
Barthel, BL; Burkhart, DJ; Colvin, SM; Kirby, TP; Koch, TH; Rudnicki, DL, 2012)		2.05

Dosage Studied

ExcerptRelevanceReference
"The results in this study suggest that FOLFIRI, a common regimen combining irinotecan and 5-FU, should switch the dosing sequence, namely from 5-FU to irinotecan, to enhance hydrolytic activation of irinotecan."( Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
Charpentier, M; Guo, L; Lu, W; Xiao, D; Yan, B; Yang, D, 2013)		0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID297711Growth inhibition of human RXF393 cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297705Growth inhibition of human HL60(TB) cells after 48 hrs by crystal violet assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297722Induction of apoptosis in HL60 cells assessed as annexin V positive cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID272794Growth inhibition of HepG2 cells by crystal violet assay after 3 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID272789Growth inhibition of MCF7/Adr cells by crystal violet assay after 3 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID297699Growth inhibition of human SHP77 cells after 3 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID272796Growth inhibition of rat H9c2(2-1) cells by MTT assay after 3 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID272798Cytotoxicity against Vero cells by MTT assay after 3 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID297707Growth inhibition of human HCT116 cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID468900Toxicity in athymic nude mouse xenografted with human NCI-H1435 cells expressing CES2 gene assessed as lipid peroxidation in hepatocytes administered with six iv injection of 3 to 4 mg/kg by hematoxylin/eosin staining-based microscopy2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.
AID297701Growth inhibition of human PC3 cells after 3 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID272792Growth inhibition of SK-HEP-1 cells by crystal violet assay after 3 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID297710Growth inhibition of human IGROVI cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297721Induction of apoptosis in human HCT116 cells at 200 nM for 3 hrs by annexin V staining assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297712Growth inhibition of human DU145 cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297706Growth inhibition of human NCIH460 cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297717Effect on G2/M arrest in topoisomerase 2 deficient human HL60/MX2 cells at 100 nM after 24 hrs2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297720Induction of apoptosis in human HCT116 cells at 50 nM for 3 hrs by annexin V staining assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297704Growth inhibition of human BxPc3 cells after 3 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID272799Cytotoxicity against Vero cells by MTT assay after 24 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID297708Growth inhibition of human SF268 cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297723Induction of apoptosis in topoisomerase 2 deficient HL60/MX2 cells assessed as annexin V positive cells2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID272788Growth inhibition of MCF7 cells by crystal violet assay after 3 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases.
AID297715Induction of apoptosis in human HCT116 cells at 400 nM for 3 hrs relative to control cells by annexin V staining assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297719Inhibition of topoisomerase 2 at 50 nM by decatenation assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297702Growth inhibition of human MDA-MB-435 cells after 3 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297709Growth inhibition of human UACC257 cells after 48 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297703Growth inhibition of human MiaPaCa2 cells after 3 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
AID297700Growth inhibition of human A375 cells after 3 hrs by MTT assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's7 (58.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.520amino-acid anion
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.1310aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		7.0810nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		3.81001,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.4920delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.2510benzenes;
phenyl acetates
irinotecan
[no description available]		7.4920carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		2.211017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
oxazolidine
oxazolidine: structure given in first source		2.1310oxazolidine
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		2.0810beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
doxoform
doxoform: a doxorubicin-formaldehyde conjugate; structure in first source		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0510
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0510